News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 22, 2020SUBA™-Itraconazole to be Tested in Combination with Standard of Care Chemotherapy for Metastatic Castrate Resistant Prostate Cancer
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous...
-
Nov 25, 2019SUBA™-Itraconazole to be Tested in Combination with Standard of Care Chemotherapy for Metastatic Castrate Resistant Prostate Cancer
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous...
-
Aug 19, 2019New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™-Itraconazole, Inhibiting the Hedgehog Signaling Pathway
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit the progression of...
-
May 29, 2019New method of use claims in lung cancer enhance HedgePath’s intellectual property estate relating to SUBA‐Itraconazole
TAMPA, FL, MAY 29, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to...
-
May 6, 2019Twenty new claims for use of itraconazole as a means of Hedgehog pathway inhibition Patent expected to issue coincident with HedgePath’s 2019 efforts to clear IND for SUBA®-Itraconazole for the treatment of prostate cancer
TAMPA, FL, MAY 6, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative...